Keros to Start Rinvatercept DMD Trial in Q1 2026, Plans ALS Regulatory Talks
Keros Therapeutics plans a phase II DMD trial of rinvatercept in Q1 2026 and regulatory talks for ALS in H2 2026. Cash stands at $383 million with runway into H1 2028.
Keros Therapeutics
CompanyRelated News
Guardant Health CMO to Resign; Delfi and Singular Name New Leaders
Guardant Health said its chief medical officer will resign effective May 8, while Delfi Diagnostics appointed Charles Newton to its board and Singular Genomics named John Stark CEO.
Myelofibrosis Pipeline Expands with Over 40 Candidates from 35+ Companies
The myelofibrosis therapeutic pipeline now includes over 40 candidates from more than 35 companies, with recent developments including Orphan Drug Designation for CK0804 and multiple Phase III trial initiations. Key clinical milestones include completed enrollment in Karyopharm's SENTRY trial and upcoming Phase I data from Incyte's combination therapy studies.